BGM0504 Research Reference

Catalog classification, reference sizes, lab math links, and source-backed data. Educational use only — not medical advice.

Researched for: PepTools vendor-neutral scientific reference catalog

Investigational peptide dual GLP-1 receptor/GIP receptor agonist compound Reference needs_revision Best effort · source review pending

Also known as: BGM-0504, BGM 0504

Best-effort research profile: this record has not passed full two-source scientific verification. Descriptive fields, research protocols, storage/handling notes, and interaction guidance below are shown with their evidence labels, but calculator presets and exact dosing math remain hidden until the record is verified or reaches Community-Supported status.

Quick Facts

Reference Sizes
Not standardized / source review pending

Best-Effort Research Profile

BGM0504 is a molecular-dynamics-guided, peptide-based GLP-1R/GIPR dual agonist under clinical investigation for metabolic indications including type 2 diabetes and obesity. Preclinical studies reported dual-receptor agonism and glucose- and weight-related effects in animal models. Early human studies evaluated subcutaneous administration with pharmacokinetic behavior supporting once-weekly dosing.

Source review pending. This descriptive profile is shown from the available source material as a best-effort educational reference. It has not passed the full verification bar and is not a dosing instruction, medical claim, or treatment recommendation.

Research Profile

Administration Routes (Research)
Subcutaneous injection

Reported Research Effects

Reflects preclinical/research literature context only. Not a medical claim, dosing instruction, or treatment recommendation.

Research Notes

A phase I study in healthy volunteers evaluated a 2.5 mg single dose followed by once-weekly titration to 5, 10, and 15 mg; pharmacokinetic exposure was reported as dose-proportional across 2.5–15 mg and supportive of once-weekly administration. A phase II study in Chinese adults with type 2 diabetes evaluated subcutaneous BGM0504 at 5, 10, and 15 mg once weekly for 12 weeks following titration. These are study regimens reported in clinical research and are not dosing recommendations. A 2024 preclinical study reported molecular-dynamics-guided optimization, receptor agonism, and effects in diabetic and obesity-related animal models.

Supplementary research context only. Not medical advice or a treatment recommendation.

Source-Backed Observations

BGM0504 is an investigational compound; the reviewed authoritative sources did not establish an approved nonproprietary name, CAS identifier, PubChem record, or standardized chemical identifier. Published literature describes it as a peptide-based GLP-1R/GIPR dual agonist.

Reflects published research. Educational reference — not a recommendation for use.

Sources Under Review

Molecular dynamics-guided optimization of BGM0504 enhances dual-target agonism for combating diabetes and obesity
https://www.nature.com/articles/s41598-024-66998-8 (accessed 2026-09-25)
Evaluation of the Safety, Efficacy and Pharmacokinetics of BGM0504 in Chinese Adults With Type 2 Diabetes: A Multicentre, Randomised, Controlled and Double-Blind Phase II Trial
https://pmc.ncbi.nlm.nih.gov/articles/PMC13341324/ (accessed 2026-09-25)
A Study of BGM0504 in Chinese Patients With Type 2 Diabetes, NCT06974825
https://clinicaltrials.gov/study/NCT06974825 (accessed 2026-09-25)

Suggest a community source

Found a relevant Reddit or forum thread about this compound? Suggest it below. Every suggestion is reviewed by an editor before it appears -- nothing is published automatically.

Related Research Articles

Published articles on this site that mention BGM0504 or one of its catalog aliases.

Related Research Tools

Research Use Only. All content is for educational and research reference only. Not medical advice, a treatment recommendation, or guidance on human use. Compounds are not FDA-approved drugs unless specifically noted.

Scroll to Top